0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover1410.40%IV-73.58%PremiumDec 13, 2024Expiry Date5.57Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9691Delta0.0096Gamma1.33Leverage Ratio-0.1178Theta0.0001Rho1.29Eff Leverage0.0004Vega
Recursion Pharmaceuticals Stock Discussion
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class Cdk7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
No comment yet